Roche Unveils Newborn Screening Test For 3 Genetic Conditions Of SMA, SCID, Sickle Cell Disease

India, Sept. 30 -- Swiss drug major Roche Holding AG (RHHBY,RO.SW,ROG.SW) announced Wednesday the launch of newborn screening test for three severe genetic conditions, such as Spinal Muscular Atrophy or SMA, Severe Combined Immunodeficiency Disease or SCID, and Sickle Cell Disease or SCD, simultaneously.

TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The LightMix Newborn TREC/SMN1/HBB kit runs on established LightCycler systems.

SMA is a genetic neuromuscular disorder causing progressive degeneration of nerve cells in the spinal cord, leading to muscle weakness. SCID is a group of rare, life-threateni...